Biophytis Deploys Its Partnership Strategy and Signs Two Contracts With Local Agents in Asia
Biophytis Deploys Its Partnership Strategy and Signs Two Contracts With Local Agents in Asia
Japan and China are two strategic markets for Biophytis. Indeed, Japan has the largest population in the world suffering from sarcopenia, with more than 1 in 5 people aged 60 and over affected (source: Yuan 2023, Epidemiology of Sarcopenia, Metabolism). Additionally, more than 70 million Chinese adults are affected by obesity, making it the second-largest population worldwide with this pathology (source: ).PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 22, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today announces the deployment of its partnership strategy in Asia.
2024年7月22日，位於法國巴黎和馬薩諸塞州劍橋市的生物醫藥公司Biophytis SA（Euronext Growth Paris：ALBPS）（“Biophytis”或“公司”），宣佈在亞洲部署合作伙伴策略。該公司是一家專注於開發面向衰老疾病治療的臨床階段生物技術公司。
To expand its presence in this strategic region, Biophytis has today signed two contracts with local agents: one for Japan and South Korea, the other for China and Southeast Asia. These agents will leverage their networks within the pharmaceutical sector to support Biophytis in identifying partners for the drug candidate BIO101 (20-hydroxyecdysone) in these different countries.
爲了擴大在這一關鍵地區的影響力，Biophytis已經與當地代理商簽訂了兩份合同：一份涉及日本和韓國，另一份涉及中國和東南亞。這些代理商將利用其在藥品領域內的網絡，支持Biophytis在這些不同的國家尋找候選藥物BIO101（20-羥基蛻皮酮）的合作伙伴。
This initiative is part of the partnership development strategy in Asia, aimed at accelerating the deployment of BIO101 in this key geography, the second largest pharmaceutical market in the world. Biophytis is determined to establish successful collaborations to meet patients' needs and make significant advances in the various targeted pathologies.
這一舉措是該公司在亞洲推行合作伙伴發展策略的一部分，旨在加速在全球第二大藥品市場的關鍵地理位置部署BIO101。Biophytis決心建立成功的合作關係，以滿足患者需求，並在各種有針對性的病理狀況方面取得重要進展。
Japan and China are two strategic markets for Biophytis. Indeed, Japan has the largest population in the world suffering from sarcopenia, with more than 1 in 5 people aged 60 and over affected (source: Yuan 2023, Epidemiology of Sarcopenia, Metabolism). Additionally, more than 70 million Chinese adults are affected by obesity, making it the second-largest population worldwide with this pathology (source: ).
日本和中國是Biophytis的兩個戰略市場。實際上，日本擁有全球最多患有肌無力症的人口，超過五分之一的60歲及以上人群受影響（來源：Yuan 2023年《肌無力症流行病學》）。此外，有超過7000萬中國成年人患有肥胖症，成爲全球第二大的這種病理人口（來源：).
Following the exclusive license agreement signed with Blanver, one of the leading pharmaceutical companies in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin America, Biophytis aims to sign new co-development and commercialization agreements with industrial partners in Asia and also in North America, the world's largest pharmaceutical market.
在與巴西領先製藥公司Blanver簽署BIO101（20-羥基蛻皮酮）在拉丁美洲的獨家許可協議後，Biophytis旨在與亞洲和北美的工業合作伙伴簽署新的共同開發和商業化協議，這是全球最大的藥品市場。
****
****
About BIOPHYTIS
關於Biophytis
Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy, phase 1-2 study to be started, respiratory (Covid-19, phase 2 completed) and metabolic diseases (obesity, phase 2 to be started). The company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825). For more information, visit
Biophytis SA是一家臨床生物技術公司，專注於開發面向年齡相關疾病的候選藥物。BIO101（20-羥基蛻皮激素）是我們的主導藥物候選藥物，是一種小分子藥物，用於肌肉（肌肉萎縮，第3期待啓動和杜興肌肉萎縮，第1-2期即將啓動）、呼吸（COVID-19，第2期已完成）和代謝性疾病（肥胖症，第2期將啓動）的研究。該公司總部位於法國巴黎和美國馬薩諸塞州的劍橋。公司普通股在Euronext Growth上市（Ticket：ALBPS - ISIN: FR0012816825）。了解更多信息，請訪問
Forward-looking statements
前瞻性聲明 本新聞稿中包括的關於未來表現和結果、預期、規劃、策略、重點、承諾和其他聲明（包括與我們社會、環境和其他可持續性目標有關的聲明）的非歷史事實的前瞻性聲明，是根據美國聯邦證券法的定義而作出的前瞻性聲明。本新聞稿中關於我們環境和其他可持續性計劃和目標的前瞻性聲明以及其他聲明並不意味着這些聲明對於投資者、我們的業務、運營結果、財務狀況、前景或策略、對我們在可持續發展事項上的影響或其他當事方來說均是重要的，或者必須披露在我們向證券交易委員會（“SEC”）或其他監管機構的備案中。此外，歷史、現有及未來涉及社會、環境和可持續性的相關聲明可能是基於仍在發展的衡量進展的標準、不斷演變的內部控制和流程以及假設，在將來可能會發生變化。前瞻性聲明基於當前的信仰、期望和假設，並受到可能導致實際結果與前瞻性聲明有實質性差異的重大風險、不確定性和情況變化的影響。
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company's 2023 Financial Report available on BIOPHYTIS website () and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
本新聞稿包含前瞻性聲明。前瞻性聲明包括所有非歷史事實陳述。 在某些情況下，您可以通過使用“前景展望”，“相信”，“期望”，“潛力”，“繼續，”，“可能”，“將” ，“應該”，“可能”，“尋求”，“預測”，“打算”，“趨勢”，“計劃”，“估計”，“預計” 或這些詞的負面版本或其他可比較的詞語來識別這些前瞻性陳述。 這類前瞻性聲明是基於Biophytis認爲合理的假設。然而，不能保證這些前瞻性陳述中包含的陳述將得到證實，這些陳述還可能受到各種風險和不確定性的影響。此 新聞稿中包含的前瞻性聲明也可能受到 Biophytis 尚未了解或目前不認爲重要的風險的影響。因此，存在或將存在重要因素可能導致實際結果或成果與這些聲明中指示的結果存在重大差異。此外，請參閱 Biophytis 網站上可用的2023年財務報告中的“公司即將面臨的風險與不確定性”部分以及20-F表格中的“風險因素”部分以及提交給美國證券交易委員會（SEC）的其他表格。我們沒有義務公開更新或審查任何前瞻性聲明，無論是因爲新的信息，未來的發展還是其他情況，除非法律要求。
Contacts Biophytis
Biophytis聯繫方式
Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com
投資者關係
Nicolas Fellmann，CFO
Investors@biophytis.com
Media
媒體
Antoine Denry: antoine.denry@taddeo.fr - +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50
安託萬·登裏：antoine.denry@taddeo.fr - +33 6 18 07 83 27
尼澤爾·貝拉達：nizar.berrada@taddeo.fr - +33 6 38 31 90 50
SOURCE: Biophytis
來源：Biophytis
譯文內容由第三人軟體翻譯。
